Limbrel
flavocoxid
(fla-vo-cox-id) ,Limbrel
(trade name)Classification
Therapeutic: nonopioid analgesicsPharmacologic: flavanoids
Indications
Dietary management of osteoarthritis; considered to be a medical food product.
Action
Anti-inflammatory and analgesic properties related to inhibition of prostaglandin synthesis by inhibiting cyclo-oxygenase (not COX-2 selective) and other mediators of inflammation.
Therapeutic effects
Decreased pain/inflammation associated with osteoarthritis, with improved mobility.
Pharmacokinetics
Absorption: Some intestinal conversion prior to absorption, remainder unknown.
Distribution: Unknown.
Metabolism and Excretion: Mostly metabolized by the liver.
Half-life: Unknown.
Time/action profile (analgesic effect)
ROUTE | ONSET | PEAK | DURATION |
---|---|---|---|
PO | within 1–2 hr | unknown | 12 hr |
Contraindications/Precautions
Contraindicated in: Hypersensitivity; Obstetric / Lactation / Pediatric: Not recommended.
Use Cautiously in: History of GI bleeding.
Adverse Reactions/Side Effects
Cardiovascular
- ↑ BP
- ↑ in varicose veins
Gastrointestinal
- GI upset
Dermatologic
- psoriasis
Interactions
Drug-Drug interaction
None noted.Route/Dosage
Oral (Adults) 250 mg every 12 hr (up to 250 mg three times daily has been used).
Availability
Capsules: 250 mg
Nursing implications
Nursing assessment
- Assess pain (note type, location, and intensity), range of motion, degree of swelling, and stiffness in affected joints before and periodically during therapy.
Potential Nursing Diagnoses
Chronic pain (Indications)Implementation
- Oral: Administer flavocoxid twice daily.
Patient/Family Teaching
- Instruct patient to take flavocoxid as directed. Do not increase does without consulting health care professional.
Evaluation/Desired Outcomes
- Decrease in pain and stiffness, and improved mobility in patients with osteoarthritis.
Drug Guide, © 2015 Farlex and Partners